Category:Alternative Chemotherapy

Alternative Chemotherapy

Blah

	Drug Name	Overall Survival without PBT	Overall Survival with PBT	Progression-Free Survival without PBT	Progression-Free Survival with PBT	Usefulness Rating	toxicity level	Toxicity Explanation
Chronotherapy	Chronotherapy with Temozolomide (TMZ)	13.5 months for general cases, 19.5 months for patients with MGMT methylated tumors.	17 months for general cases, 25.5 months for patients with MGMT methylated tumors when administered in the morning.	Standard progression statistics for GBM.	Improved in morning dosing, exact data still under investigation.	4	Comparable to standard TMZ treatments, but timing affects management of side effects.	Morning administration of TMZ shows potential for increased efficacy, with manageable increases in side effects.
Metronomic low dose temozolomide (TMZ)	Metronomic Low-Dose Temozolomide (TMZ)	Median overall survival for GBM is typically 15-17 months from diagnosis	Studies suggest a potential improvement in overall survival, with some reports indicating up to 20-24 months in certain patient populations	Data not specified	Progression-free survival of 6-12 months reported in some studies	4	3	Generally well-tolerated but requires careful monitoring for hematologic toxicity and other side effects. The low-dose approach aims to minimize severe adverse effects associated with standard TMZ dosing.

Loading comments...

The following 2 pages are in this category, out of 2 total.